A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever.
| Member | Definition | Class |
|---|
| 2-thiosalicylic acid | A sulfanylbenzoic acid that is the 2-sulfanyl derivative of benzoic acid. | thiosalicylic acid |
| acetaminophen | A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. | paracetamol |
| alminoprofen | A substituted aniline that is ibuprofen in which the isobutyl group is replaced by a (2-methylprop-2-en-1-yl)amino group. A non-steroidal anti-inflammatory drug, it is used for treatment of inflammatory and rheumatic disorders. | alminoprofen |
| amfenac | An oxo monocarboxylic acid that is benzophenone in which one of the phenyl groups is substituted by an amino group and a carboxymethyl group at position 2 and 3, respectively. The corresponding carboxamide, nepafenac, is a prodrug of amfenac and is used for the treatment of pain and inflammation following cataract surgery. | amfenac |
| aminopyrine | A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties. | aminophenazone |
| ampyrone | A pyrazolone, a member of the class of pyrazoles that is antipyrine substituted at C-4 by an amino group. It is a metabolite of aminopyrine and of metamizole. | 4-aminoantipyrine |
| antipyrine | A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2. | antipyrine |
| aspirin | A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity. | acetylsalicylic acid |
| benoxaprofen | A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals. | benoxaprofen |
| bufexamac | A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties. | bufexamac |
| bumadizone | A carbohydrazide obtained by formal condensation of one of the carboxy groups from butylmalonic acid with the hydrazino group of 1,2-diphenylhydrazine. Used (as its calcium semihydrate) for treatment of rheumatoid arthritis. | bumadizone |
| clonixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a (2-methyl-3-chlorophenyl)amino group. Used (as its lysine salt) for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin |
| diclofenac | A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position. | diclofenac |
| difenpiramide | A monocarboxylic acid amide obtained by formal condensation of the carboxy group from biphenyl-4-ylacetic acid with the amino group of 2-aminopyridine. Used for treatment of rheumatoid arthritis. | difenpiramide |
| dipyrone | A pyrazole that is antiipyrine substituted at C-4 by a methyl(sulfomethyl)amino group, the sodium salt of which, metamizole sodium, was widely used as a powerful analgesic and antipyretic, but withdrawn from many markets from the 1970s due to a risk of causing risk of causing agranulocytosis. | metamizole |
| dipyrone | An organic sodium salt of antipyrine substituted at C-4 by a methyl(sulfonatomethyl)amino group, commonly used as a powerful analgesic and antipyretic. | metamizole sodium |
| etodolac | A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active. | etodolac |
| fenoprofen | A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. | fenoprofen |
| fenoprofen calcium | The dihydrate form of the calcium salt of fenoprofen. A non-steroidal anti-inflammatory drug, it is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. | fenoprofen calcium |
| flufenamic acid | An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders. | flufenamic acid |
| flunixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a 2-methyl-3-(trifluoromethyl)phenylamino group. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine (usually as the meglumine salt) for treatment of horses, cattle and pigs. | flunixin |
| flunixin meglumine | An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine for treatment of horses, cattle and pigs. | flunixin meglumine |
| flurbiprofen | A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. | flurbiprofen |
| friedelin | A pentacyclic triterpenoid that is perhydropicene which is substituted by an oxo group at position 3 and by methyl groups at the 4, 4a, 6b, 8a, 11, 11, 12b, and 14a-positions (the 4R,4aS,6aS,6bR,8aR,12aR,12bS,14aS,14bS-enantiomer). It is the major triterpenoid constituent of cork. | friedelin |
| ibuprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group. | ibuprofen |
| ketoprofen | An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. | ketoprofen |
| lornoxicam | A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations. | lornoxicam |
| loxoprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration. | loxoprofen |
| lysine clonixinate | An organoammonium salt obtained by combining clonixin with one molar equivalent of L-lysine. Used for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin lysine salt |
| meclofenamate sodium anhydrous | A hydrate that is the monohydrate of the sodium salt of meclofenamic acid. It is used for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | sodium meclofenamate monohydrate |
| meclofenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | meclofenamic acid |
| mefenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. | mefenamic acid |
| miroprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(imidazo[1,2-a]pyridin-2-yl)phenyl group. A non-steroidal anti-inflammatory drug that also exhibits analgesic, antipyretic and platelet aggregation inhibition properties. | miroprofen |
| mobiflex | A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries. | tenoxicam |
| naproxen | A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes. | naproxen |
| naproxen sodium | An organic sodium salt consisting of equimolar amounts of naproxen(1-) anions and sodium anions. | naproxen sodium |
| naproxol | An aromatic ether in which the substituents on oxygen are 6-[(2S)-1-hydroxypropan-2-yl]-2-naphthyl and methyl. | naproxol |
| noramidopyrine | A member of the class of pyrazoles that is antipyrine substituted at C-4 by a methylamino group. It is a metabolite of aminopyrine and of metamizole. | 4-(methylamino)antipyrine |
| oxyphenbutazone | A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. | oxyphenbutazone |
| pirfenidone | A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis. | pirfenidone |
| proglumetacin | A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining. | proglumetacin |
| salicin | An aryl beta-D-glucoside that is salicyl alcohol in which the phenolic hydrogen has been replaced by a beta-D-glucosyl residue. | salicin |
| solasodine | An oxaspiro compound and steroid alkaloid sapogenin with formula C27H43NO2 found in the Solanum (nightshade) family. It is used as a precursor in the synthesis of complex steroidal compounds such as contraceptive pills. | solasodine |
| sulindac | A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. | sulindac |
| tepoxalin | A hydroxamic acid obtained by formal condensation of the carboxy group of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid with the amino group of N-methylhydroxylamine. It is used in veterinary medicine for the control of pain and inflammation caused by musculoskeletal disorders such as hip dysplasia and arthritis in dogs. | tepoxalin |
| tofisopam | An organic sodium salt having loxoprofen(1-) as the counterion. The parent acid, loxoprofen, is a prodrug that is rapidly converted to its active trans-alcohol metabolite following oral administration. | loxoprofen sodium |
| valdecoxib | A member of the class of isoxazoles that is isoxazole which is substituted at positions 3, 4 and 5 by phenyl, p-sulfamoylphenyl and methyl groups, respectively. A selective cyclooxygenase 2-inhibitor, it used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of arthritis from 2001 until 2005, when it was withdrawn following concerns of an associated increased risk of heart attack and stroke. | valdecoxib |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 31.1551 | 1 | 7 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 17.3515 | 1 | 4 |
| 67.9K protein | Vaccinia virus | Potency | 15.2608 | 2 | 8 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 51.4468 | 2 | 6 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 7.0795 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 22.4417 | 2 | 7 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 30.9068 | 1 | 9 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 24.8678 | 10 | 56 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 27.3175 | 2 | 12 |
| arylsulfatase A | Homo sapiens (human) | Potency | 11.3833 | 1 | 4 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.3245 | 2 | 11 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 2.1721 | 2 | 5 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 0.1510 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 0.0744 | 2 | 8 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 53.1764 | 1 | 2 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 21.0632 | 1 | 2 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 3.7578 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 21.0632 | 1 | 2 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 3.7578 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 33.4438 | 2 | 11 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 26.7115 | 1 | 12 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 18.7199 | 1 | 3 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 15.7912 | 1 | 4 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 37.0814 | 1 | 3 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 53.1764 | 1 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 9.6924 | 1 | 9 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.2382 | 1 | 3 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 6.4091 | 1 | 4 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 37.0814 | 1 | 3 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 65.1022 | 2 | 15 |
| ClpP | Bacillus subtilis | Potency | 31.6228 | 1 | 1 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 6.3944 | 1 | 2 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 12.3524 | 1 | 6 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 19.2982 | 1 | 12 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 20.7004 | 1 | 9 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.7952 | 2 | 20 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 12.2585 | 2 | 10 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 40.8606 | 1 | 6 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 6.4776 | 1 | 2 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 68.8664 | 1 | 4 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 29.8357 | 1 | 2 |
| endonuclease IV | Escherichia coli | Potency | 17.7828 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 23.0555 | 12 | 70 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 18.8065 | 3 | 15 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 38.0549 | 7 | 47 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 13.9560 | 1 | 18 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 14.6591 | 4 | 24 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 25.1730 | 4 | 9 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 15.6724 | 1 | 3 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 3.9811 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 19.2982 | 1 | 12 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.7952 | 1 | 10 |
| geminin | Homo sapiens (human) | Potency | 11.1004 | 2 | 19 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 17.5726 | 2 | 17 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 25.4181 | 2 | 3 |
| GLS protein | Homo sapiens (human) | Potency | 27.4040 | 2 | 13 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 10.9656 | 1 | 3 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 18.3609 | 4 | 9 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 53.2310 | 1 | 3 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 6.5131 | 1 | 1 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 18.8541 | 1 | 2 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 27.9443 | 1 | 2 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 16.9531 | 2 | 6 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 14.2510 | 2 | 28 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 20.1052 | 1 | 4 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 38.8075 | 2 | 9 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 66.7580 | 2 | 5 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 79.4328 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 19.2982 | 1 | 12 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 32.1220 | 1 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 21.5656 | 2 | 7 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 8.8363 | 2 | 14 |
| IDH1 | Homo sapiens (human) | Potency | 15.4810 | 1 | 5 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 66.2026 | 2 | 2 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 19.2982 | 1 | 24 |
| Interferon beta | Homo sapiens (human) | Potency | 24.6369 | 3 | 19 |
| interleukin 8 | Homo sapiens (human) | Potency | 70.9011 | 1 | 2 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 4.9268 | 1 | 11 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 17.3926 | 1 | 2 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 32.4030 | 3 | 24 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 1.0000 | 2 | 2 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.6362 | 2 | 10 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 4.4761 | 2 | 2 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 2.2387 | 1 | 1 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 42.7900 | 1 | 5 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 1.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 1.0000 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 12.6714 | 2 | 4 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 8.6218 | 1 | 5 |
| Nrf2 | Homo sapiens (human) | Potency | 8.5003 | 2 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 43.1893 | 3 | 19 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 22.1134 | 1 | 4 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 28.4555 | 1 | 6 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 14.7722 | 1 | 2 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 25.7532 | 2 | 8 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 34.3558 | 3 | 20 |
| P53 | Homo sapiens (human) | Potency | 14.1254 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 22.9833 | 1 | 2 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 14.3766 | 2 | 6 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 64.5923 | 1 | 3 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 26.2199 | 4 | 22 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 31.8326 | 1 | 2 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 26.3188 | 5 | 13 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.0843 | 2 | 5 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 2.6790 | 1 | 2 |
| polyprotein | Zika virus | Potency | 3.9811 | 1 | 1 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 17.6684 | 1 | 5 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| PPM1D protein | Homo sapiens (human) | Potency | 35.0126 | 1 | 4 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 31.9696 | 3 | 12 |
| progesterone receptor | Homo sapiens (human) | Potency | 23.5730 | 2 | 10 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 26.2943 | 2 | 19 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 6.3096 | 1 | 1 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 13.5720 | 1 | 3 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 25.7492 | 3 | 24 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 15.9674 | 3 | 25 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.7975 | 1 | 3 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 26.8221 | 2 | 14 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 26.8221 | 2 | 14 |
| Smad3 | Homo sapiens (human) | Potency | 12.0502 | 1 | 4 |
| snurportin-1 | Homo sapiens (human) | Potency | 66.2026 | 2 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 26.4131 | 1 | 6 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.3146 | 1 | 3 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 13.5385 | 1 | 9 |
| TDP1 protein | Homo sapiens (human) | Potency | 15.0660 | 2 | 30 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 51.3695 | 1 | 4 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 26.9894 | 4 | 18 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 32.1975 | 3 | 22 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 31.5510 | 2 | 2 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 10.4401 | 5 | 16 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 11.2202 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 6.4776 | 1 | 2 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 2.6790 | 1 | 2 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 2.6790 | 1 | 2 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 38.6036 | 2 | 8 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 25.2721 | 2 | 9 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 20.7394 | 4 | 17 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 18.5540 | 5 | 11 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 53.2310 | 1 | 3 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 1.7500 | 1 | 4 |
| 5-lipoxygenase | Bos taurus (cattle) | IC50 | 35.0000 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 235.1100 | 1 | 1 |
| Acid-sensing ion channel 1 | Rattus norvegicus (Norway rat) | IC50 | 276.1997 | 5 | 10 |
| Acid-sensing ion channel 3 | Rattus norvegicus (Norway rat) | IC50 | 370.9740 | 1 | 2 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 2,348.3333 | 1 | 3 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 2,348.3333 | 1 | 3 |
| Albumin | Bos taurus (cattle) | IC50 | 3.0000 | 1 | 1 |
| Albumin | Homo sapiens (human) | Ki | 212,690,740,000.0000 | 1 | 5 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 0.2930 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 83.4483 | 3 | 6 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 2.9270 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 2.9030 | 1 | 1 |
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | IC50 | 17.2850 | 4 | 6 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | IC50 | 27.0312 | 3 | 8 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | Ki | 0.8100 | 1 | 1 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | IC50 | 8.1325 | 7 | 12 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | Ki | 0.2200 | 1 | 1 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | IC50 | 3.4649 | 11 | 17 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | Ki | 1.1800 | 3 | 3 |
| Aldo-keto reductase family 1 member C4 | Homo sapiens (human) | IC50 | 100.0000 | 2 | 7 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 305.0000 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Arachidonate 5-lipoxygenase-activating protein | Homo sapiens (human) | IC50 | 44.0000 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 9 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 | 43.5450 | 1 | 1 |
| Beta-carbonic anhydrase 1 | Mycobacterium tuberculosis H37Rv | Ki | 12.9700 | 3 | 3 |
| Beta-lactamase | Escherichia coli K-12 | IC50 | 350.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 330.0139 | 5 | 33 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 369.3750 | 1 | 4 |
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | IC50 | 5.0060 | 2 | 2 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Rattus norvegicus (Norway rat) | Ki | 5.1000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 8 |
| Carbonic anhydrase | Candida albicans SC5314 | Ki | 0.7002 | 3 | 4 |
| Carbonic anhydrase | Methanosarcina thermophila | Ki | 0.1850 | 2 | 2 |
| Carbonic anhydrase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 61.0000 | 1 | 1 |
| Carbonic anhydrase | Saccharomyces cerevisiae S288C | Ki | 0.6540 | 1 | 1 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 5.7100 | 1 | 1 |
| Carbonic anhydrase | Anopheles gambiae (African malaria mosquito) | Ki | 0.1640 | 1 | 1 |
| Carbonic anhydrase | Astrosclera willeyana | Ki | 0.5170 | 1 | 1 |
| Carbonic anhydrase | Cryptococcus neoformans var. grubii | Ki | 0.7040 | 1 | 1 |
| Carbonic anhydrase | Mycobacterium tuberculosis H37Rv | Ki | 7.8100 | 1 | 1 |
| Carbonic anhydrase | Nakaseomyces glabratus CBS 138 | Ki | 0.0970 | 1 | 1 |
| Carbonic anhydrase | Stylophora pistillata | Ki | 0.0287 | 2 | 2 |
| Carbonic anhydrase | Sulfurihydrogenibium sp. YO3AOP1 | Ki | 0.0053 | 1 | 1 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 559.7739 | 5 | 16 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 217.3873 | 40 | 52 |
| Carbonic anhydrase 12 | Homo sapiens (human) | Ki | 106.6481 | 7 | 18 |
| Carbonic anhydrase 13 | Homo sapiens (human) | Ki | 0.4250 | 1 | 1 |
| Carbonic anhydrase 13 | Mus musculus (house mouse) | Ki | 139.0161 | 3 | 14 |
| Carbonic anhydrase 14 | Homo sapiens (human) | Ki | 137.5862 | 3 | 14 |
| Carbonic anhydrase 15 | Mus musculus (house mouse) | Ki | 2.4835 | 3 | 4 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 429.5908 | 6 | 17 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 97.2313 | 46 | 58 |
| Carbonic anhydrase 2 | Mycobacterium tuberculosis H37Rv | Ki | 0.6820 | 2 | 2 |
| Carbonic anhydrase 3 | Homo sapiens (human) | Ki | 185.9067 | 4 | 15 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | IC50 | 50.5626 | 3 | 9 |
| Carbonic anhydrase 4 | Bos taurus (cattle) | Ki | 0.3400 | 2 | 2 |
| Carbonic anhydrase 4 | Homo sapiens (human) | Ki | 120.6200 | 5 | 16 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Ki | 194.1723 | 3 | 14 |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | Ki | 157.9706 | 3 | 14 |
| Carbonic anhydrase 6 | Homo sapiens (human) | Ki | 151.4872 | 5 | 17 |
| Carbonic anhydrase 7 | Homo sapiens (human) | Ki | 114.1294 | 6 | 17 |
| Carbonic anhydrase 9 | Homo sapiens (human) | IC50 | 50.0135 | 2 | 4 |
| Carbonic anhydrase 9 | Homo sapiens (human) | Ki | 86.8636 | 12 | 24 |
| Carbonic anhydrase, alpha family | Hydrogenovibrio crunogenus XCL-2 | Ki | 0.5290 | 1 | 1 |
| caspase recruitment domain family, member 15 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Caspase-1 | Homo sapiens (human) | IC50 | 27.0533 | 1 | 15 |
| Caspase-3 | Homo sapiens (human) | IC50 | 27.0533 | 1 | 15 |
| Caspase-4 | Homo sapiens (human) | IC50 | 27.0533 | 1 | 15 |
| Caspase-5 | Homo sapiens (human) | IC50 | 27.0533 | 1 | 15 |
| Caspase-9 | Homo sapiens (human) | IC50 | 27.0533 | 1 | 15 |
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | Ki | 0.0430 | 1 | 1 |
| Cholinesterase | Homo sapiens (human) | IC50 | 600.0000 | 1 | 1 |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | IC50 | 96.2000 | 1 | 1 |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | IC50 | 37.0500 | 3 | 3 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 8 |
| Cytochrome P450 2C9 | Homo sapiens (human) | Ki | 57,952,000,025.0000 | 2 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 8 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 1,640.0000 | 1 | 3 |
| Dehydrogenase/reductase SDR family member 9 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Delta carbonic anhydrase | Conticribra weissflogii | Ki | 0.3780 | 1 | 1 |
| Delta-type opioid receptor | Mus musculus (house mouse) | Ki | 27.0215 | 2 | 2 |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0430 | 1 | 1 |
| Dihydrofolate reductase | Homo sapiens (human) | Ki | 1,918.4000 | 1 | 5 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 10.5000 | 1 | 2 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 10.0000 | 1 | 4 |
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | Ki | 66.1250 | 2 | 8 |
| Fatty acid-binding protein, liver | Rattus norvegicus (Norway rat) | Ki | 488.6035 | 2 | 10 |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | IC50 | 100.6667 | 2 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 1 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 | 80.0000 | 1 | 1 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 | 63.1250 | 3 | 4 |
| Glutathione hydrolase 1 proenzyme | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | IC50 | 1.2000 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Integrin beta-3 | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Interleukin-8 | Homo sapiens (human) | IC50 | 0.0080 | 1 | 1 |
| Lactoylglutathione lyase | Homo sapiens (human) | Ki | 435.3750 | 3 | 8 |
| leucine aminopeptidase | Homo sapiens (human) | IC50 | 0.3100 | 1 | 1 |
| M1-family alanyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 47.5850 | 2 | 2 |
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 0.7050 | 2 | 2 |
| M18 aspartyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 | 10.0200 | 1 | 1 |
| Malate dehydrogenase, cytoplasmic | Homo sapiens (human) | IC50 | 225.0000 | 1 | 1 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 | 3.1440 | 1 | 1 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 | 165.4000 | 1 | 1 |
| Mothers against decapentaplegic homolog 3 | Mus musculus (house mouse) | IC50 | 1.4300 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 2.9000 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0430 | 1 | 1 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 54.0000 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 9 |
| Myc proto-oncogene protein | Homo sapiens (human) | IC50 | 403.0000 | 1 | 1 |
| Myeloperoxidase | Homo sapiens (human) | IC50 | 67.7300 | 3 | 3 |
| Myoglobin | Homo sapiens (human) | IC50 | 2.3000 | 1 | 1 |
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | IC50 | 25.0000 | 1 | 1 |
| Nicotinate phosphoribosyltransferase | Homo sapiens (human) | Ki | 0.0005 | 1 | 6 |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | IC50 | 50.0000 | 1 | 1 |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | IC50 | 0.0200 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 | 28.0117 | 10 | 11 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 28.3800 | 1 | 1 |
| Prostaglandin E synthase | Homo sapiens (human) | IC50 | 80.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 72.9483 | 44 | 64 |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | IC50 | 0.2200 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 581.6052 | 83 | 127 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | Ki | 62.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 5.0000 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 887.8471 | 7 | 16 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 | 1.1756 | 9 | 9 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 197.5510 | 93 | 134 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 | 0.2039 | 11 | 13 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 347.8520 | 29 | 41 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Ki | 52.0000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | Ki | 9.0000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | IC50 | 600.3000 | 2 | 5 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 | 1.3012 | 8 | 8 |
| Prostaglandin-H2 D-isomerase | Mus musculus (house mouse) | IC50 | 750.1000 | 1 | 2 |
| receptor-interacting serine/threonine-protein kinase 2 isoform 1 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | IC50 | 82.9000 | 1 | 1 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | IC50 | 6,700.0000 | 1 | 1 |
| Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 2 |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | IC50 | 44.2500 | 2 | 3 |
| Serum paraoxonase/arylesterase 1 | Homo sapiens (human) | Ki | 4,441.6667 | 1 | 3 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 2.9270 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 2.9030 | 1 | 1 |
| Solute carrier family 22 member 20 | Mus musculus (house mouse) | Ki | 51.3878 | 1 | 4 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | IC50 | 10.2857 | 2 | 7 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | IC50 | 0.5000 | 1 | 1 |
| Solute carrier family 22 member 6 | Mus musculus (house mouse) | Ki | 347.0521 | 1 | 4 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Ki | 444.0833 | 2 | 6 |
| Solute carrier family 22 member 7 | Rattus norvegicus (Norway rat) | Ki | 1.8400 | 1 | 1 |
| Solute carrier family 22 member 8 | Homo sapiens (human) | Ki | 1,165.0000 | 1 | 2 |
| Solute carrier organic anion transporter family member 1A1 | Rattus norvegicus (Norway rat) | Ki | 126.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A3 | Rattus norvegicus (Norway rat) | Ki | 1,900.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A4 | Rattus norvegicus (Norway rat) | Ki | 2,430.0000 | 1 | 1 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 1.7500 | 1 | 2 |
| Transcription factor SOX-18 | Mus musculus (house mouse) | IC50 | 191.5000 | 2 | 4 |
| Transcriptional enhancer factor TEF-3 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| Transforming growth factor beta-1 proprotein | Mus musculus (house mouse) | IC50 | 1.4300 | 1 | 1 |
| Transient receptor potential cation channel subfamily M member 2 | Homo sapiens (human) | IC50 | 88.0000 | 2 | 3 |
| Transthyretin | Homo sapiens (human) | IC50 | 2.9000 | 1 | 1 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | Ki | 23.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | Ki | 52.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A10 | Homo sapiens (human) | Ki | 28.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 1A7 | Homo sapiens (human) | Ki | 19.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A9 | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 131.0000 | 1 | 3 |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.3000 | 1 | 2 |